Letter on: Pre-Emptive Initiation of Continuous Renal Replacement Therapy in Patients With Acute Liver Failure With Cerebral Edema Improves Outcomes: A Randomized Controlled Trial [0.03%]
关于连续肾脏替代疗法的预防起始治疗脑水肿急性肝衰患者的随机对照试验的来信：改善了患者的预后
Shumaila Ashfaq Ahmed Mangi,Omar Alfauri,Pawan Kumar et al.
Shumaila Ashfaq Ahmed Mangi et al.
Risk of Myeloproliferative Neoplasms in Patients With Inflammatory Bowel Disease and Impact on Outcomes: A Multi-Centre Matched Analysis [0.03%]
炎症性肠病患者的骨髓增生性肿瘤风险及对预后的影响：多中心匹配分析
Mohamed H Eldesouki,Ahmed Ibrahim,Muhammed M Marey et al.
Mohamed H Eldesouki et al.
Background: Inflammatory bowel disease (IBD) and myeloproliferative neoplasms (MPNs) share chronic inflammation and immune dysregulation. Aim: ...
Biomarkers in Liver Transplantation for Hepatocellular Carcinoma: Towards Precision Medicine [0.03%]
肝细胞癌肝脏移植的生物标志物：迈向精准医疗
Yule Ma,Huigang Li,Huan Chen et al.
Yule Ma et al.
Background: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide. For eligible patients, liver transplantation is a curative treatment option, but recurrence after transplantation...
Elobixibat Versus Prucalopride in Functional Constipation: A Prospective Comparative Effectiveness Study [0.03%]
与普鲁卡必利相比，依洛倍西巴治疗功能性便秘的疗效：一项前瞻性比较有效性研究
Omesh Goyal,Manjeet Kumar Goyal,Bhupinder Singh et al.
Omesh Goyal et al.
Background and aims: The choice of second-line therapy in functional constipation (FC) is often empirical, owing to the lack of direct comparisons between agents with distinct mechanisms of action. Elobixibat, an ileal bi...
A Distinct Immune Signature Characterizes Cirrhosis in Ethiopian Individuals With Chronic HBV Infection [0.03%]
慢性HBV感染的埃塞俄比亚患者肝硬化具有独特的免疫特征
Julia MacLeod,Fikadu G Gudissa,Asiya Jeylan et al.
Julia MacLeod et al.
Background and aims: The immune cell phenotype of African patients living with chronic hepatitis B virus (HBV) infection is rarely described, despite high infection rates. This study investigated the differences in immune...
Review Article: The Impact of the Gut Microbiome on Ulcerative Colitis Pharmacotherapy [0.03%]
系统评价文章：肠道菌群对溃疡性结肠炎药物治疗的影响
Kate Collins,Srinivas Kamath,Rachel H Davis et al.
Kate Collins et al.
Background: Ulcerative colitis (UC) is a chronic immune-mediated condition of the gastrointestinal tract with highly variable treatment responses. Current therapies focus on suppressing inflammation through aminosalicylat...
Letter: Interpreting P-CAB Superiority for Antithrombotic Gastroprotection Beyond Acid Suppression. Authors' Reply [0.03%]
致编辑的信：P-CAB对抗血小板药物胃保护优势解读——作者回信
Min Joo Yoon,Soyoung Lee,Hye-Kyung Jung et al.
Min Joo Yoon et al.
Letter: Low FODMAP Therapy in Paediatric Irritable Bowel Syndrome: Balancing Efficacy, Expectancy and Safety [0.03%]
致编辑：儿科肠易激综合征的低FODMAP疗法：平衡疗效，期望和安全性
Yousef Hakimi,Edward Giles
Yousef Hakimi
Letter: Assessing Pruritus Efficacy With Peroxisome Proliferator-Activated Receptor Agonists in Primary Biliary Cholangitis Must Include Grading the Strength of Trial Evidence [0.03%]
来信：使用过氧化物酶体增殖激活受体激动剂评估原发性胆汁性肝硬化瘙痒疗效必须包括分级试验证据质量
Daria B Crittenden,Gideon M Hirschfield
Daria B Crittenden
Review Article: Advances in the Diagnosis of Dysplasia in Barrett's Oesophagus [0.03%]
巴雷特食管异型增生诊断进展评审文章
Michelle S Russin,Natalie J Wilson,Nicholas Mordan et al.
Michelle S Russin et al.
Background: Barrett's oesophagus (BE), the precursor to oesophageal adenocarcinoma, progresses through a stepwise dysplastic sequence. Accurate dysplasia detection is critical, as endoscopic eradication therapy is highly ...